RxDoctor Payments Data

Kevin Bluemel, MD

Family Medicine · Brodhead, WINPI 1689697260

Payments from drug & device makers

$1,045in general payments, 2019–2025

Across 82 payments — averaging $12.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$324
  • Pfizer$208
  • Novartis$146
  • GSK$111
  • Novo Nordisk$97
  • Boehringer Ingelheim$62
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$1,02498%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,045 in reported general payments places this provider in the 85th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$112,189
Medicare patients
281
Services billed
1,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$176,000
OzempicSemaglutide42$62,564
JardianceEmpagliflozin38$55,763
XareltoRivaroxaban53$53,560
JanuviaSitagliptin Phosphate23$28,607
Spiriva RespimatTiotropium Bromide23$21,188
Breo ElliptaFluticasone/Vilanterol33$19,768
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,144
FarxigaDapagliflozin Propanediol20$14,086
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$13,979
BrilintaTicagrelor12$13,275
MyrbetriqMirabegron15$10,658
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$9,450
Xigduo XrDapaglifloz Propaned/Metformin12$9,287
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$208$176,000162 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$62$81,95672 claims
Novo NordiskOzempic$97$62,56442 claims
Johnson & JohnsonXarelto$15$53,56053 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$111$40,74862 claims
MerckJanuvia, Belsomra$51$33,66535 claims
AstraZenecaFarxiga, Brilinta$324$27,36132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Brodhead

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →